After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced ... announcement had a similar effect, with the stock up just over 5% at the time of writing.

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...

Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Hims and Hers is airing an ad about its copycat GLP-1 drugs during Sunday’s Super Bowl. Critics say it violates FDA rules.

3 Big news is also expected from some of the major players; for example, Eli Lilly is aiming to conclude a phase III trial of an oral GLP-1 drug orforglipron in type 2 diabetes. As the drug is a ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...